Santhera Gets Bad News from FDA on Duchenne Drug Approval

Source: The Street

Jul 14, 2016

Santhera Pharmaceuticals -- a Swiss biotech company -- had the U.S. approval its Duchenne muscular dystrophy drug pushed back to 2020 after the FDA said a second, successful phase III study would be required.

The company had hoped to persuade the FDA to accept an accelerated approval filing for Raxone based on a single, already completed phase III study -- but the FDA turned them down. Santhera shares fell 38% following the news.

Santhera is developing Raxone to improve the lung function of Duchenne patients.

Read The Street coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments